Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) (SHINE-RLS)
Advancing Dialyzer Technology: Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients
研究概览
详细说明
Patients with end-stage kidney disease (ESKD) on regular high-flux hemodialysis (HD) often experience an accumulation of middle-molecule uremic toxins, which are linked to systemic inflammation and troubling symptoms such as restless legs syndrome (RLS), severe itching, and poor sleep quality. While traditional high-flux dialysis efficiently clears small molecules, its ability to remove larger middle-molecule toxins (like α1-microglobulin [α1-MG]) is limited. Current alternatives such as online hemodiafiltration (HDF) have limitations, highlighting the need for new treatment approaches. Super High-Flux Hemodialysis (SHFHD) offers enhanced clearance of these middle molecules while preserving serum albumin levels and maintaining patient safety.
In this study, the investigators evaluate the effectiveness and safety of SHFHD compared with high-flux HD in patients undergoing maintenance HD, focusing on α1-MG removal and its potential effect on RLS. The investigators also explore the multiple diverse effects of SHFHD on the changes of cardiovascular risk factors including bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.
It is to conduct a randomized, controlled, crossover trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. The investigators will stratify participants by baseline RLS. Participants will receive either SHFHD or high-flux HD for 12 weeks, followed by a 4-week washout and crossover. The study outcome measures are difference in change-from-baseline values of α1-MG reduction ratio, RLS severity (International Restless Legs Scale), albumin levels, clearance of β2-microglobulin, free light chains, inflammatory markers, pruritus scores, and quality of life. Safety will be assessed via albumin maintenance, adverse events, and hemodynamic stability.
This will be the first RCT directly evaluating SHFHD for α1-MG removal and RLS outcomes, addressing critical knowledge gaps and potentially informing new dialysis prescription strategies.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Wan-Chuan Tsai, M.D., Ph.D.
- 电话号码:1780 886-289667000
- 邮箱:mkks618@gmail.com
学习地点
-
-
Banciao Dist.
-
New Taipei City、Banciao Dist.、台湾、220
- Far Eastern Memorial Hospital
-
接触:
- Wan-Chuan Tsai, M.D., Ph.D.
- 电话号码:1780 886-277281780
- 邮箱:mkks618@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Diagnosis of Restless Legs Syndrome according to standard criteria.
- Age ≥ 20 years.
- Maintenance high-flux hemodialysis for ≥ 3 months.
- Stable vascular access (AV fistula or AV graft).
- Adequate dialysis delivery (URR ≥ 65% or Kt/V(daugirdes) ≥ 1.2).
- Sufficient iron stores (serum ferritin ≥ 200 ng/mL, TSAT ≥ 20%).
- Clinically stable condition for the past 4 weeks.
- Able and willing to comply with study protocol
Exclusion Criteria:
- Low-flux HD or temporary catheter use
- Serum albumin < 2.5 g/dL
- Recent hospitalization (within 4 weeks)
- Scheduled kidney transplantation
- Active malignancy or infection
- Pregnancy
- Any condition impairing protocol adherence
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Super High-Flux HD
Receives 12 weeks of Super High-Flux HD (Elisio™-HX)
|
Participants receive hemodialysis using a Type V super high-flux dialyzer (such as Elisio™-HX or Theranova) for 12 weeks to assess the clearance of middle-molecule uremic toxins and its effect on RLS symptoms.
|
|
无干预:High-Flux HD
Receives 12 weeks of High-Flux HD as usual care
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in α1-microglobulin (α1-MG) Reduction Ratio
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of α1-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit.
The primary outcome is the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in International Restless Legs Scale (IRLS) Score
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
IRLS score assesses the severity of Restless Legs Syndrome (ranging from 0 to 40, where higher scores indicate greater severity).
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Albumin Level
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Monitored to evaluate nutritional safety and albumin preservation during Super High-Flux HD compared to High-Flux HD.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses sleep quality.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in 5-D Itch Scale Score
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses pruritus severity.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in health-related quality of life (EQ-5D-5L) Score
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses quality of life.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in β2-microglobulin [β2-MG] Reduction ratio
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of β2-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Kappa Free Light Chains Reduction ratio
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Lambda Free Light Chains Reduction ratio
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum interleukin-6 (IL-6) Level
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum High-sensitivity C-reactive Protein (hs-CRP) Level
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Indoxyl Sulfate Level
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum P-cresol Sulfate Level
大体时间:Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- FEMH-IRB-TSAI2025
- FEMH-IIT-2026-01 (其他赠款/资助编号:Far Eastern Memorial Hospital)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.